Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma
- PMID: 24989696
- PMCID: PMC4448967
- DOI: 10.1002/cncr.28883
Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma
Comment on
-
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.Cancer. 2014 Nov 1;120(21):3311-9. doi: 10.1002/cncr.28875. Epub 2014 Jul 2. Cancer. 2014. PMID: 24989332 Free PMC article. Clinical Trial.
References
-
- Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666–1680. - PubMed
-
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636–2644. - PubMed
-
- Ujiie H, Buitrago D, Nitadori J, et al. CD8 T-cell infiltration and tumor IL-7R expression are independent prognostic factors in epithelioid malignant pleural mesothelioma; Published Abstract presented at 15th World Conference on Lung Cancer; October 29, 2013; Sydney, Australia.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
